retlirafusp alfa

News

Hengrui has achieved a milestone in oncology as retlirafusp alfa is approved in China, its first world market, for gastric cancer.

News

Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.